Phase III multinational trial: alectinib vs platinum-based chemotherapy in advanced/metastatic ALK-positive NSCLC patients previously treated with platinum-based doublet chemotherapy and crizotinib. This evidence concerns the gene ALK and non-small cell lung carcinoma.